Related Experiment Video
Updated: May 12, 2026
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
Comprehensive analysis of m6A RNA methylation regulators for prognostic risk stratification and immune
Fei-Fei Kong1,2, Jiawei Feng3, Jing-Ya Liu1,4
1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Objectives:
Despite mounting evidence of N6-methyladenosine (m6A) dysregulation in colorectal cancer (CRC), comprehensive prognostic association analysis remains limited. We systematically investigated m6A modification patterns and developed a robust risk stratification model.
Methods:
We analyzed 27 m6A regulators in 488 CRC samples and 42 normal controls from TCGA, with external validation in two independent cohorts (n=762). Consensus clustering identified distinct m6A modification patterns. A prognostic risk model incorporating 268 m6A-associated genes was constructed using multivariate Cox regression.
Results:
24 of 27 m6A regulators exhibited significant differential expression (p<0.001). Multivariate analysis identified ZC3H13, LRPPRC, and IGFBP3 as independent prognostic factors. The risk model showed exceptional performance across all validation cohorts (HR: 8.59-14.27, p<0.0001), maintaining significance in early-stage patients. High-risk patients exhibited significantly elevated PD-L1 expression levels (p=5.7 × 10-9 to 5 × 10-7) and altered immune cell infiltration patterns.
Conclusions:
Our findings reveal pervasive m6A dysregulation with superior predictive performance compared to conventional approaches. The links between RNA methylation and tumor immunity establish m6A signatures as actionable biomarkers for precision oncology.
